证券代码：002581 证券简称：ST 未名 公告编号：2026-007 山东未名生物医药股份有限公司 关于放弃优先购买控股子公司少数股权的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假记 载、误导性陈述或重大遗漏。 一、交易概述 山东未名生物医药股份有限公司（以下简称"公司"）持有控股子公司天津 未名生物医药有限公司（以下简称"天津未名"）60.5653%股权，醴陵市云石泰 裕投资合伙企业（有限合伙）（以下简称"云石泰裕投资"）参股持有天津未名 19.7174%股权。 近期，公司获悉云石泰裕投资拟委托福建省顶信拍卖有限公司公开拍卖其 持有的天津未名 19.7174%股权（以下简称"交易标的"）。根据《中华人民共和 国公司法》及天津未名《公司章程》约定，公司作为天津未名股东，在同等条 件下对该部分股权享有优先购买权。 基于公司整体战略规划与实际情况，公司拟放弃前述控股子公司天津未名 少数股权的优先购买权。本次放弃优先购买权不改变公司持有的天津未名股权 比例，公司仍为天津未名的控股股东，公司合并报表范围亦未发生改变。公司 已于 2026 年 3 月 17 日召开第六届董事会第十一次会 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司(以下简称"公司")第六届董事会第十一次 会议于 2026 年 3 月 17 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实 际参加表决董事 11 人，分别为：岳家霖、刘文俊、徐隽雄、周婷、陈星、史晓如、 黄桂源、蔡艳红、张荣富、杨军、夏阳。董事会会议通知已于 2026 年 3 月 15 日 以通讯方式发出，会议由公司董事长岳家霖先生主持。本次董事会的召集和召开 符合国家有关法律法规、《董事会议事规则》及《公司章程》的规定。本次会议 审议了如下议案： 二、董事会会议审议情况 （一）审议通过了《关于放弃优先购买控股子公司少数股权的议案》 持有公司控股子公司天津未名生物医药有限公司（以下简称"天津未名"） 19.7174%股权的股东醴陵市云石泰裕投资合伙企业（有限合伙）拟委托福建省顶 信拍卖有限公司公开拍卖其持有的天津未名股权。根据《中华人民共和国公司法》 及天津未名《公司章程》约定，公司作为天津未名股东，在同等条件下对该部分 股权享有优先购买权。 ...

Core Viewpoint - ST Unimed (SZ002581) experienced a trading halt with a price of 8.4 yuan, reflecting a 5% increase, and a total market capitalization of 5.542 billion yuan, driven by positive developments in its business operations and market conditions [1][2]. Group 1: Company Developments - The subsidiary of the company obtained a pharmaceutical operating license, which is expected to enhance its pharmaceutical industry chain layout and positively impact long-term business development [2]. - The company won a legal case to recover 34% of its equity in Xiamen Unimed and received compensation, strengthening its control over related business operations [2]. - The company's losses for 2025 narrowed by 34.46% to 59.95% year-on-year, indicating an improvement in operational conditions and effectiveness in strategic adjustments or cost control [2]. Group 2: Market and Technical Analysis - The biopharmaceutical sector showed active performance on February 27, 2026, contributing to a sector-wide momentum that benefited the company, which specializes in interferon, nerve growth factors, and vaccines [2]. - Technical indicators such as the MACD may form a golden cross, and short-term moving averages are in a bullish arrangement, suggesting potential upward momentum [2]. - There was a net inflow of large orders on that day, indicating that major funds are paying attention to and participating in the stock, which contributed to the price increase [2].

山东未名生物医药股份有限公司 关于持股 5%以上股东股份减持完成的公告 公司持股5%以上股东高宝林先生及其一致行动人王明贤先生保证向本公司提 供的信息真实、准确和完整，没有虚假记载，误导性陈述或者重大遗漏；本公司及 董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 11 月 29 日在巨潮资讯网披露了《关于持股 5%以上股东减持股份的预披露公告》（公告 编号：2025-084），持有公司 5%以上股份的股东高宝林先生及其一致行动人王 明贤先生，因自身资金需求，计划自该公告披露之日起 15 个交易日后的 3 个月 内以集中竞价方式、大宗交易方式或两种方式相结合减持公司股份，减持数量合 计不超过 19,792,067 股的公司股份（占公司总股本比例 3%）。 2026 年 1 月 14 日，公司在巨潮资讯网披露《关于持股 5%以上股东权益变动 比例触及 1%整数倍的公告》（公告编号：2026-001）。该次减持完成后，高宝 林先生及其一致行动人王明贤先生合计持有公司股份由 74,622,800 股下降至 70,622,800 股，占公司总 ...

证券代码：002581 证券简称：ST未名 公告编号：2026-005 山东未名生物医药股份有限公司 关于持股 5%以上股东权益变动比例触及 1%整数倍的公告 公司持股5%以上股东高宝林先生保证向本公司提供的信息真实、准确和完整， 没有虚假记载，误导性陈述或者重大遗漏；本公司及董事会全体成员保证公告内容 与信息披露义务人提供的信息一致。 山东未名生物医药股份有限公司（以下简称"公司"）于 2025 年 11 月 29 日在巨潮资讯网披露了《关于持股 5%以上股东未来减持计划预披露的公告》（公 告编号：2025-084），持有公司 5%以上股份的股东高宝林先生及其一致行动人 王明贤先生，因自身资金需求，计划自该公告披露之日起 15 个交易日后的 3 个 月内以集中竞价方式、大宗交易方式或两种方式相结合减持公司股份，减持数量 合计不超过 19,792,067 股的公司股份（占公司总股本比例 3%）。 2026 年 1 月 14 日，公司在巨潮资讯网披露《关于持股 5%以上股东权益变动 比例触及 1%整数倍的公告》（公告编号：2026-001）。该次减持完成后，高宝 林先生及其一致行动人王明贤先生合计持有公司股份由 ...

Group 1 - The core transaction of ST Weiming on February 3 involved 1.5454 million shares traded, with a total transaction value of 10.5551 million yuan, accounting for 21.38% of the total trading volume for that day [1] - The transaction price was 6.83 yuan per share, representing a discount of 9.54% compared to the market closing price of 7.55 yuan [1] Group 2 - Multiple transactions of ST Weiming on the same day included various trading volumes, with the highest being 39,000 shares at the same price of 6.83 yuan, executed by different brokerage firms [2] - The total transaction amounts for these trades varied, with the highest being 266.37 thousand yuan for each of the 39,000 shares traded [2]

Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

Group 1 - The core point of the article is that ST Weiming (SZ002581) reached its daily limit with a price of 7.55 yuan, reflecting a 5.01% increase and a total market capitalization of 4.981 billion yuan [1] - The stock price surge is attributed to several factors including the approval of the innovative drug SMR001 eye drops for clinical phase III, which targets a 18 billion yuan dry eye market and showcases the company's technological strength in the pharmaceutical field [2] - The company's operational status has improved, with the 2025 annual report indicating a reduction in losses to between 90 million and 55 million yuan, a year-on-year decrease of 34.46% to 59.95%, enhancing market expectations for future profitability [2] Group 2 - A subsidiary of the company has obtained a pharmaceutical operating license, which enhances the pharmaceutical supply chain layout and includes a 6,000 square meter modern logistics facility that can improve operational efficiency [2] - Although specific funding data for the day is not available, the improvement in the company's fundamentals is likely to attract investor attention [2] - There is no technical analysis provided, but the positive operational changes are expected to influence investor expectations regarding the stock price trend [2]

Summary of Key Points Core Viewpoint - On January 30, ST Weiming executed a block trade of 1.5 million shares, amounting to 10.62 million yuan, which represented 25.05% of the total trading volume for the day, with a transaction price of 7.08 yuan, reflecting a discount of 3.8% compared to the market closing price of 7.36 yuan [1]. Group 1: Trade Details - The block trade involved a total of 1.5 million shares at a price of 7.08 yuan per share [1]. - The total transaction value for the block trade was 10.62 million yuan [1]. - The trade accounted for 25.05% of the total trading volume on that day [1]. Group 2: Trading Parties - The buyers included multiple brokerage firms such as Industrial Securities, Guotou Securities, and Jianghai Securities [2]. - The sellers were primarily from Huatai Securities, with various branches involved in the transaction [2]. - Each buyer purchased 50,000 shares, resulting in a total of 354,000 yuan for each transaction [2].

Core Viewpoint - ST Unimed (002581.SZ) forecasts a significant loss for the fiscal year 2025, with projected revenue between 355 million to 398 million yuan and a net loss attributable to shareholders ranging from 55 million to 90 million yuan, compared to a loss of 137 million yuan in the same period last year [1] Financial Performance - The company expects to report a revenue of 355 million to 398 million yuan for the fiscal year 2025 [1] - The net loss attributable to shareholders is projected to be between 55 million to 90 million yuan, an improvement from the previous year's loss of 137 million yuan [1] - The net profit after deducting non-recurring gains and losses is anticipated to be a loss of 70 million to 105 million yuan, compared to a loss of 111 million yuan in the previous year [1] Operational Challenges - The primary reason for the company's losses is the suspension of production and sales by its subsidiary, Tianjin Unimed Biopharmaceutical Co., Ltd., which has adversely affected related business revenue [1] - The company is actively working on rectification to promote the resumption of production, but ongoing costs and expenses continue to contribute to the losses [1]